Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PAC 113

Drug Profile

PAC 113

Alternative Names: P 113L; PAC-113; PAC-113 Mouth Rinse

Latest Information Update: 22 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Demegen
  • Developer Demegen; General Biologicals Corporation; Pacgen Life Science Corporation
  • Class Antibacterials; Antifungals; Peptide antibiotics; Peptides
  • Mechanism of Action Cell membrane permeability enhancers; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Candidiasis
  • Discontinued Gingivitis; Mucositis

Most Recent Events

  • 22 Jul 2016 Phase-II clinical trials in Candidiasis in Taiwan (PO) before July 2016
  • 24 Jan 2014 Pacgen Life Science enter into a sublicensing agreement with General Biological Corporation for PAC 113 for any oral condition (excluding transitional skin-mucous membrane areas) and also for vaginal, dermatological and ophthalmic conditions
  • 30 Apr 2012 Pacgen Biopharmaceuticals is now called Pacgen Life Science Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top